同和药业（300636）(300636.SZ)公告，公司近日从国家药品监督管理局药品审评中心(CDE)"原辅包登 记信息公示"平台查询获悉，公司提交的"富马酸伏诺拉生"原料药通过了CDE审批。富马酸伏诺拉生主 要用于治疗反流性食管炎。 ...

智通财经APP讯，同和药业(300636.SZ)公告，公司近日从国家药品监督管理局药品审评中心(CDE)"原 辅包登记信息公示"平台查询获悉，公司提交的"富马酸伏诺拉生"原料药通过了CDE审批。富马酸伏诺 拉生主要用于治疗反流性食管炎。 ...

格隆汇2月25日丨同和药业(300636.SZ)公布，近日从国家药品监督管理局药品审评中心（CDE）"原辅 包登记信息公示"平台查询获悉，公司提交的"富马酸伏诺拉生"原料药通过了CDE审批。公司"富马酸伏 诺拉生"原料药通过CDE审批，表明该原料药符合中国相关药品审评技术标准，已批准在国内上市制剂 中使用，有利于公司拓展产品在国内市场的销售，形成国内国外市场同步销售的良好格局。 ...

Core Viewpoint - Xinhua Pharmaceutical (SZ000756) experienced a trading halt with a price of 17.16 yuan, marking a 10% increase and a total market capitalization of 11.837 billion yuan, driven by recent drug approvals, innovation in drug development, and improved cash flow [1] Group 1: Company Developments - Xinhua Pharmaceutical has recently obtained registration certificates for several drugs, including Fumaric Acid Vorinostat, Alendronate Sodium, and Fumaric Acid Bisoprolol, enhancing its product line in cardiovascular and digestive system treatments [1] - The company received clinical trial approval for its first-class innovative drug LXH-1211 tablets, indicating significant progress in its drug development efforts, which lays a foundation for long-term growth [1] - The net cash flow from operating activities for Q3 2025 increased by 26.65% year-on-year, reflecting improved financial management and boosting market confidence in the company [1] Group 2: Industry Context - The pharmaceutical industry remains a focal point for market attention, with innovative drug development being a critical direction for industry growth [1] - Companies within the pharmaceutical sector that have made research breakthroughs have seen active stock performance, suggesting that Xinhua Pharmaceutical's recent innovations may attract market investment [1] - Technical indicators suggest that the stock price may break through key resistance levels, potentially drawing in more investors and contributing to the stock's trading halt [1]

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the marketing application of fumaric acid volnorelin, which is primarily used for gastroesophageal reflux disease and is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] Group 1 - The approval of fumaric acid volnorelin will enhance the company's product line [1] - This new product is expected to improve the company's overall competitiveness in the pharmaceutical market [1]

Core Viewpoint - The approval of fumaric acid volnorasone as a chemical raw material drug by the National Medical Products Administration enhances the company's product line and overall competitiveness in the pharmaceutical market [1][2]. Group 1: Product Approval - The company received the approval notice for fumaric acid volnorasone, with the notification number 2025YS00988 [1]. - The application for the domestic production of fumaric acid volnorasone was submitted in March 2024 and was accepted by the National Medical Products Administration [1]. - The approval for production was granted in November 2025, confirming the product's evaluation conclusion as approved [1]. Group 2: Market Potential - Fumaric acid volnorasone is primarily used for gastroesophageal reflux disease and is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1]. - The estimated sales revenue for fumaric acid volnorasone-related formulations in Chinese public medical institutions is approximately RMB 825 million in 2024 [1]. Group 3: Competitive Advantage - The approval of this product will further enrich the company's product line, thereby enhancing its comprehensive competitiveness in the pharmaceutical industry [2].

Core Viewpoint - The approval of fumaric acid volnorasone by the National Medical Products Administration enhances the company's product line and competitiveness, with potential sales in public medical institutions projected at approximately 825 million yuan in 2024 [1] Group 1: Product Approval - The company has received approval for fumaric acid volnorasone, which is primarily used for reflux esophagitis [1] - The application for market registration was submitted in March 2024 and has been accepted [1] Group 2: Market Potential - The product is classified as a Category B item in the medical insurance catalog, indicating its relevance in the healthcare market [1] - The estimated sales revenue for related formulations in Chinese public medical institutions is around 825 million yuan in 2024 [1] Group 3: Competitive Landscape - The approval is expected to enrich the company's product portfolio, thereby enhancing its competitive position in the pharmaceutical market [1] - However, the sales of the drug may be influenced by various factors, including policies and market conditions, leading to uncertainties [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of fumaric acid volnorelin, which is primarily used for treating gastroesophageal reflux disease [1] Group 1 - The drug fumaric acid volnorelin has been approved for marketing, indicating a significant milestone for the company [1] - This approval may enhance the company's product portfolio and potentially increase revenue from the treatment of gastroesophageal reflux disease [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the marketing application of fumaric acid volnorasone, which is primarily used for treating gastroesophageal reflux disease [1] Group 1 - The approval signifies a regulatory milestone for the company, potentially enhancing its product portfolio in the pharmaceutical market [1] - Fumaric acid volnorasone is specifically indicated for gastroesophageal reflux disease, indicating a targeted therapeutic application [1]

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the marketing application of Fumaric Acid Venlafaxine, which is primarily used for gastroesophageal reflux disease [1] Group 1 - The approval notification for Fumaric Acid Venlafaxine marks a significant milestone for the company in expanding its product portfolio [1] - The drug is specifically indicated for the treatment of reflux esophagitis, addressing a common gastrointestinal condition [1]